State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Department of Infectious Diseases, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, China.
J Med Virol. 2022 Aug;94(8):3613-3624. doi: 10.1002/jmv.27759. Epub 2022 Apr 19.
The Delta variant has gradually replaced the Alpha variant as the major strain of SARS-COV-2 infection worldwide. We extracted the clinical characteristics and outcomes information about 381 hospitalized patients infected with Delta variant and compared them with 856 patients diagnosed with Alpha variant infection in Zhejiang Province. The majority (85.3%) of patients infected with the Delta variant had received inactivated vaccine. The patients' condition was generally mild. Most of them were mild (35.7%) and common (62.7%) types. Only six patients (1.5%) were severe/critical types. During the follow-up period, patients infected with the Delta variant had longer hospital stays than the Alpha variant (24 [21-26] vs. 18 [14-24], p < 0.001). In addition, the unvaccinated patients infected with the Delta variant had a higher proportion of severe/critical cases than vaccinated patients (11.11% vs. 0.92%, p = 0.024) and a higher usage rate of glucocorticoids (38.89 vs. 14.77%, p = 0.017) and antibiotics (55.56% vs. 32.31%, p = 0.042) during hospitalization. The vaccine's efficacy against severe COVID-19 did not diminish over time for patients who received two doses of the inactivated vaccine. The disease types and clinical manifestations were generally mild in patients infected with the Delta variant, possibly associated with widespread vaccination with inactivated vaccines in China.
德尔塔变异株已逐渐取代阿尔法变异株,成为全球范围内 SARS-CoV-2 感染的主要株。我们提取了 381 例感染德尔塔变异株住院患者的临床特征和结局信息,并与浙江省 856 例感染阿尔法变异株患者进行比较。大多数(85.3%)感染德尔塔变异株的患者接种过灭活疫苗。患者病情一般较轻,大多数为轻症(35.7%)和普通型(62.7%),仅 6 例(1.5%)为重型/危重型。随访期间,感染德尔塔变异株患者的住院时间长于感染阿尔法变异株患者(24[21-26]vs.18[14-24],p<0.001)。此外,未接种疫苗的德尔塔变异株感染患者重型/危重型比例高于接种疫苗者(11.11%vs.0.92%,p=0.024),住院期间使用糖皮质激素(38.89%vs.14.77%,p=0.017)和抗生素(55.56%vs.32.31%,p=0.042)的比例也较高。对于接种两剂灭活疫苗的患者,疫苗对重症 COVID-19 的保护效果随时间推移并未减弱。感染德尔塔变异株的患者疾病类型和临床表现一般较轻,这可能与中国广泛接种灭活疫苗有关。